New Publication from DC CFAR Investigator and CPS Core Director, Princy Kumar, MD

Dr. Princy Kumar Photo
August 27, 2018
DC CFAR investigator and Clinical and Population Sciences (CPS) Core Director Princy Kumar, MD, along with her colleagues, has published an article in The New England Journal of Medicine entitled, "Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1". 

This article discusses a phase 3 study conducted to assess the effectiveness of Ibalizumab - a humanized IgG4 monoclonal antibody that blocks the entry of human immunodeficiency virus type 1 (HIV-1) by noncompetitive binding to CD4 - in treating adults with multidrug-resistant (MDR) HIV-1 infection in whom multiple antiretroviral therapies had failed.  Results included that at week 25 of the study, patients in the group receiving ibalizumab plus an optimized background regimen had a mean decrease of 1.6 log10 copies per milliliter from baseline; 43% of the patients had a viral load of less than 50 copies per milliliter, and 50% had a viral load of less than 200 copies per milliliter.  

Click here to read the full article.